References
- Clinical and Laboratory Standards Institute. 2005. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA
- Clinical and Laboratory Standards Institute. 2006. Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA
- Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, et al. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microb. 41: 5-14 https://doi.org/10.1128/JCM.41.1.5-14.2003
- Diekema, D. J. and R. N. Jones. 2001. Oxazolodinone antibiotics. Lancet 258: 1975-1982
- Dumitrescu, O., S. Boisset, C. Badiou, M. Bes, Y. Benito, M. E. Reverdy, F. Vandenesch, J. Etienne, and G. Lina. 2007. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob. Agents Chemother. 51: 1515-1519 https://doi.org/10.1128/AAC.01201-06
- Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, F. C. Tenover, and the Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36: 429-439 https://doi.org/10.1086/346207
- Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40: 135-136 https://doi.org/10.1093/jac/40.1.135
- Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Res. Updates 1: 135-150 https://doi.org/10.1016/S1368-7646(98)80029-0
- Komatsu, M., Y. Tajima, T. Ito, Y. Yamashiro, and K. Hiramatsu. 2008. Time-suppression test using a colorimetric probe (alamarBlue) that measures bacterial metabolic activity. Biomed. Res. 29: 171-173 https://doi.org/10.2220/biomedres.29.171
- Manome, I., M. Ikedo, Y. Saito, K. K. Ishii, and M. Kaku. 2003. Evaluation of a novel automated chemiluminescent assay system for antimicrobial susceptibility testing. J. Clin. Microbiol. 41: 279-284 https://doi.org/10.1128/JCM.41.1.279-284.2003
- Moise, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2002. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J. Antimicrob. Chemother. 50: 1017-1026 https://doi.org/10.1093/jac/dkf215
- Nagasawa, Z., I. Manome, and A. Nagayama. 2004. A rapid antimicrobial susceptibility test based on chemiluminescence assay and its application to screening of genotypes in vancomycinresistant enterococci. J. Infect. Chemother. 10: 220-226 https://doi.org/10.1007/s10156-004-0329-Z
- National Committee for Clinical Laboratory Standards. 2003. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 6th Ed. Approved Standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA
- Oliveira, G. A., A. M. Dell'Aquila, R. L. Masiero, C. E. Levy, M. S. Gomes, L. Cui, K. Hiramatsu, and E. M. Mamizuka. 2001. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect. Control Hosp. Epidemiol. 22: 443-448 https://doi.org/10.1086/501932
- Romero-Steiner, S., W. Spear, N. Brown, P. Holder, T. Hennessy, P. Gomez De Leon, and G. M. Carlone. 2004. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin. Diagn. Lab. Immunol. 11: 89-93 https://doi.org/10.1128/CDLI.11.1.89-93.2004
- Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340: 493-501 https://doi.org/10.1056/NEJM199902183400701
- Stevens, D. L., D. Herr, H. Lampiris, J. L. Hunt, D. H. Batts, and B. Hafkin. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 34: 1481-1490 https://doi.org/10.1086/340353
- Stevens, D. L., B. Dotter, and K. Madaras-Kelly. 2004. A review of linezolid: The first oxazolidinone antibiotic. Expert Rev. Anti Infect. Ther. 2: 51-59 https://doi.org/10.1586/14787210.2.1.51
- Tajima, Y., M. Komatsu, T. Ito, and K. Hiramatsu. 2007. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test. J. Microbiol. Methods 70: 434-441 https://doi.org/10.1016/j.mimet.2007.05.020
-
Yamashoji, S., I. Manome, and M. Ikedo. 2001. Menadionecatalyzed
$O_2$ - production by Escherichia coli cells: Application of rapid chemiluminescent assay to antimicrobial susceptibility testing. Microbiol. Immunol. 45: 333-340 https://doi.org/10.1111/j.1348-0421.2001.tb02628.x - Walsh, T. R. and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56: 657-675 https://doi.org/10.1146/annurev.micro.56.012302.160806
- Zurenko, G. E., J. K. Gibson, D. L. Shinabarger, P. A. Aristoff, C. W. Ford, and W. G. Tarpley. 2001. Oxazolidinones: A new class of antibacterials. Curr. Opin. Pharmacol. 1: 470-476 https://doi.org/10.1016/S1471-4892(01)00082-0